Small-cap stocks can offer big growth opportunities for investors willing to take on some risk. SBI Securities has identified five small-cap stocks with strong potential to deliver up to 38 percent returns. These companies, often lesser-known but with solid fundamentals, are poised for growth in 2025, making them worth considering for your investment portfolio.
Here are a few small-cap stocks recommended by SBI Securities with a high growth potential of up to 38 percent:
Lumax Auto Technologies Ltd
With a market capitalization of Rs. 4,211.81 crore, the shares of Lumax Auto Technologies Limited closed at Rs. 617.95 per equity share, down nearly 0.52 percent from its previous day’s close price of Rs. 621.15.
SBI Securities, a prominent brokerage firm, has recommended a “Buy” call on Lumax Auto Technologies Limited with a target price of Rs. 854 per share, indicating an upside potential of 38.20 percent.
Lumax Auto Technologies Limited was established in 1981 and is a Gurugram-based company under the D.K. Jain Group. It manufactures automotive components like gear shifters, lighting, and intake systems for two, three, and four-wheelers. With 26 facilities across India, it serves OEMs and the aftermarket, holding a leading position in gear shifters.
Force Motors Limited
With a market capitalization of Rs. 14,256.69 crore, the shares of Force Motors Limited closed at Rs. 10,939 per equity share, down nearly 1.40 percent from its previous day’s close price of Rs. 11,094.
SBI Securities, a prominent brokerage firm, has recommended a “Buy” call on Force Motors Limited with a target price of Rs. 13,200 per share, indicating an upside potential of 20.67 percent.
Force Motors Limited was established in 1958 and is a Pune-based company. It manufactures commercial vehicles, tractors, and automotive components, focusing on utility vehicles like vans and buses. The company also produces engines and axles, serving both domestic and international markets with a strong presence in India.
Amber Enterprises India Limited
With a market capitalization of Rs. 21,627.07 crore, the shares of Amber Enterprises India Limited closed at Rs. 6,390.60 per equity share, up nearly 0.69 percent from its previous day’s close price of Rs. 6,346.65.
SBI Securities, a prominent brokerage firm, has recommended a “Buy” call on Amber Enterprises India Limited with a target price of Rs. 7,160 per share, indicating an upside potential of 12.04 percent.
Amber Enterprises India Limited was established in 1990 and is a Gurugram-based company. It is a leading manufacturer of room air conditioners and components, serving as an OEM/ODM for major brands. The company also produces electronics like PCBs and HVAC solutions, with 23 manufacturing facilities across India.
Privi Speciality Chemicals Limited
With a market capitalization of Rs. 9,101.61 crore, the shares of Privi Speciality Chemicals Limited closed at Rs. 2,330 per equity share, down nearly 0.58 percent from its previous day’s close price of Rs. 2,343.55.
SBI Securities, a prominent brokerage firm, has recommended a “Buy” call on Privi Speciality Chemicals Limited with a target price of Rs. 2,662 per share, indicating an upside potential of 14.25 percent.
Privi Speciality Chemicals Limited was established in 1985 and is a Mumbai-based company. It is India’s leading manufacturer, supplier, and exporter of aroma and fragrance chemicals, serving global fragrance and flavor industries. With facilities in Maharashtra and Gujarat, Privi exports to over 50 countries, producing over 75 products.
Supriya Lifescience Limited
With a market capitalization of Rs. 5,600.80 crore, the shares of Supriya Lifescience Limited closed at Rs. 695.90 per equity share, down nearly 1.90 percent from its previous day’s closing price of Rs. 709.35.
SBI Securities, a prominent brokerage firm, has recommended a “Buy” call on Supriya Lifescience Limited with a target price of Rs. 810 per share, indicating an upside potential of 16.40 percent.
Supriya Lifescience Limited was established in 1987 and is a Mumbai-based pharmaceutical company. It manufactures active pharmaceutical ingredients (APIs) for medicines, focusing on areas like anti-histamines, vitamins, and anesthetics. The company exports to over 86 countries and has facilities in Maharashtra approved by the USFDA and EUGMP.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
